AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AgomAb Therapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026
$8.23−0.05 (-0.60%)
Close on Oct 19, 2026
Share price
+$8.22 (+82,200%)past year
Weekly closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -€62.55M
- EPS, diluted
- -143.22 EUR
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Four years at a glance
Fiscal years 2022 to 2025, EUR
Operating income
-€59.28M
Net income
-€62.55M
EPS, diluted
-143.22 EUR
Reported period